Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Concord Biotech IPO is a book built issue of Rs 1,551.00 crores. The issue is entirely an offer for sale of 2.09 crore shares.
Concord Biotech IPO bidding started from August 4, 2023 and ended on August 8, 2023. The allotment for Concord Biotech IPO was finalized on Friday, August 11, 2023. The shares got listed on BSE, NSE on August 18, 2023.
Concord Biotech IPO price band is set at ₹705 to ₹741 per share. The minimum lot size for an application is 20 Shares. The minimum amount of investment required by retail investors is ₹14,820. The minimum lot size investment for sNII is 14 lots (280 shares), amounting to ₹207,480, and for bNII, it is 68 lots (1,360 shares), amounting to ₹1,007,760.
The issue includes a reservation of up to 10,000 shares for employees offered at a discount of Rs 70 to the issue price.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited and Jefferies India Private Limited are the book running lead managers of the Concord Biotech IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Concord Biotech IPO RHP for detailed information.
| IPO Date | August 4, 2023 to August 8, 2023 |
| Listing Date | August 18, 2023 |
| Face Value | ₹1 per share |
| Price Band | ₹705 to ₹741 per share |
| Lot Size | 20 Shares |
| Total Issue Size | 20,925,652 shares (aggregating up to ₹1,551.00 Cr) |
| Offer for Sale | 20,925,652 shares of ₹1 (aggregating up to ₹1,551.00 Cr) |
| Employee Discount | Rs 70 per share |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 104,616,204 |
| Share holding post issue | 104,616,204 |
Concord Biotech IPO offers 20,925,652 shares. 4,183,130 (19.99%) to QIB, 3,137,348 (14.99%) to NII, 7,320,479 (34.98%) to RII, 10,000 (0.05%) to employees 6,274,695 (29.99%) to Anchor investors. 366,023 RIIs will receive minimum 20 shares and 3,734 (sNII) and 7,469 (bNII) will receive minimum 280 shares. (in case of oversubscription)
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 6,274,695 (29.99%) | NA |
| QIB Shares Offered | 4,183,130 (19.99%) | NA |
| NII (HNI) Shares Offered | 3,137,348 (14.99%) | |
| bNII > ₹10L | 2,091,565 (10.00%) | 7,469 |
| sNII < ₹10L | 1,045,783 (5.00%) | 3,734 |
| Retail Shares Offered | 7,320,479 (34.98%) | 366,023 |
| Employee Shares Offered | 10,000 (0.05%) | NA |
| Total Shares Offered | 20,925,652 (100%) |
Concord Biotech IPO raises Rs 464.95 crore from anchor investors. Concord Biotech IPO Anchor bid date is August 3, 2023. Concord Biotech IPO Anchor Investors list
| Bid Date | August 3, 2023 |
| Shares Offered | 6,274,695 |
| Anchor Portion Size (In Cr.) | 464.95 |
| Anchor lock-in period end date for 50% shares (30 Days) | September 10, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | November 9, 2023 |
Concord Biotech IPO opens on August 4, 2023, and closes on August 8, 2023.
| IPO Open Date | Friday, August 4, 2023 |
| IPO Close Date | Tuesday, August 8, 2023 |
| Basis of Allotment | Friday, August 11, 2023 |
| Initiation of Refunds | Monday, August 14, 2023 |
| Credit of Shares to Demat | Thursday, August 17, 2023 |
| Listing Date | Friday, August 18, 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 8, 2023 |
Investors can bid for a minimum of 20 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,820 |
| Retail (Max) | 13 | 260 | ₹192,660 |
| S-HNI (Min) | 14 | 280 | ₹207,480 |
| S-HNI (Max) | 67 | 1,340 | ₹992,940 |
| B-HNI (Min) | 68 | 1,360 | ₹1,007,760 |
| Lot Size Calculator | |||
Sudhir Vaid and Ankur Vaid are the Company Promoters.
| Share Holding Pre Issue | 44.08% |
| Share Holding Post Issue | 44.08% |
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.
The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.
Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.
| Period Ended | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 1,182.55 | 1,312.80 | 1,513.98 |
| Revenue | 630.75 | 736.35 | 888.48 |
| Profit After Tax | 234.89 | 174.93 | 240.08 |
| Net Worth | 999.37 | 1,103.22 | 1,290.00 |
| Reserves and Surplus | |||
| Total Borrowing | 86.35 | 60.59 | 31.24 |
The market capitalization of Concord Biotech IPO is Rs 7752.06 Cr.
| KPI | Values |
|---|---|
| ROE | 20.06% |
| ROCE | 24.27% |
| RoNW | 20% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 20.79 | |
| P/E (x) | 32.29 |
The objectives of the Offer are to:
[Dilip Davda] The company is an Indian biopharma company with many niche products. It marked a setback in the bottom line for FY22 but posted growth in the top line for the reported three fiscals. Based on FY23 financial performance, the issue appears fully priced. This entire issue is by way of OFS and no fund is going to the company. Well-informed investors may park funds for the medium to long-term rewards. Read detail review...
The Concord Biotech IPO is subscribed 24.87 times on August 8, 2023 7:02:00 PM. The public issue subscribed 3.78 times in the retail category, 67.67 times in the QIB category, and 16.99 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 67.67 |
| NII | 16.99 |
| bNII (bids above ₹10L) | 19.30 |
| sNII (bids below ₹10L) | 12.37 |
| Retail | 3.78 |
| Employee | 24.48 |
| Total | 24.87 |
Total Application : 1,264,369 (3.45 times)
| Listing Date | August 18, 2023 |
| BSE Script Code | 543960 |
| NSE Symbol | CONCORDBIO |
| ISIN | INE338H01029 |
| Final Issue Price | ₹741 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹741.00 |
| ₹900.05 |
| ₹900.00 |
| ₹987.05 |
| ₹941.85 |
| NSE |
|---|
| ₹741.00 |
| ₹900.05 |
| ₹900.05 |
| ₹987.70 |
| ₹942.80 |
Concord Biotech Limited
1482-86,
Trasad Road Dholka,
Ahmedabad – 382225
Phone: 079-6813 8700
Email: complianceofficer@concordbiotech.com
Website: http://www.concordbiotech.com/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: concordbiotech.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Concord Biotech IPO is a main-board IPO of 20,925,652 equity shares of the face value of ₹1 aggregating up to ₹1,551.00 Crores. The issue is priced at ₹705 to ₹741 per share. The minimum order quantity is 20 Shares.
The IPO opens on August 4, 2023, and closes on August 8, 2023.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Concord Biotech IPO using UPI as a payment gateway. Zerodha customers can apply in Concord Biotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Concord Biotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Concord Biotech IPO opens on August 4, 2023 and closes on August 8, 2023.
Concord Biotech IPO lot size is 20 Shares, and the minimum amount required is ₹14,820.
You can apply in Concord Biotech IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Concord Biotech IPO will be done on Friday, August 11, 2023, and the allotted shares will be credited to your demat account by Thursday, August 17, 2023. Check the Concord Biotech IPO allotment status.
IPO Guru (1000+ Posts, 2100+ Likes)
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
Top Contributor (400+ Posts, 200+ Likes)
IPO Mentor (500+ Posts, 400+ Likes)
